Congressmembers Langworthy, Schrier Introduce Bipartisan Bill to Lower Prescription Drug Costs by Expanding Access to Biosimilars
percent less than their brand-name counterparts. Although the FDA already requires extensive scientific evidence before approving … more affordable alternatives to high-priced brand name biologic drugs to foster greater competition and help lower drug